| Name | Title | Contact Details |
|---|
The Nimble journey began with a loved one who was sick. I found myself visiting the pharmacy multiple times per week rather than caring for my family member. This inspired me to build a different approach – an experience that centered around the patient`s needs and the provider`s workflow. My goal was that customers would LOVE the experience so much that they would tell the world about it.
Presbyterian Homes & Services (PHS), based in St. Paul, Minnesota, is a non-profit, faith-based organization providing a broad array of high quality housing choices, and care and service options for older adults. Over 7,100 employees serve more than 26,000 older adults through 59 PHS-affiliated senior living communities in Minnesota, Iowa and Wisconsin, and through Optage® home and community services. PHS is also co-owner of Genevive, the largest geriatric primary care practice in Minnesota, providing comprehensive care for over 15,000 older adults. Established in 1955, PHS has earned the reputation as an innovative leader dedicated to promoting independence, purposeful living, and overall well-being for those they serve. Today, PHS is one of the largest nonprofit providers of senior housing and services in the nation. The mission of Presbyterian Homes & Services is to honor God by enriching the lives and touching the hearts of older adults. By living our values in our daily work, we create smiles in the eyes of the people we serve. These value statements form the word “CROSS” and are central to how we do what we do: Christian Ministry - Reflect the love of God Ready and Engaged People - Create ownership and utilize strengths Operational Integrity - Do what we said we would do Service Excellence - Create an exceptional customer experience Stewardship - Optimize resources and expand ministry
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Senesco Technologies, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in New Brunswick, NJ. To find more information about Senesco Technologies, Inc., please visit www.senesco.com
Meridian Bioscience, Inc. is a fully-integrated life science company. The Companys principal businesses are the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain respiratory, gastrointestinal, viral and